CD4 and neoplasm: The immune alterations observed in vitro were broadly recapitulated in our murine model of ER+ breast cancer where the total number of CD3+ cells and the proportion of CD4+ T cells was higher in letrozole-treated tumours when compared to vehicle-treated tumours (Fig. 5).